Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Health Secur ; 22(S1): S50-S65, 2024 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-39212633

RESUMO

Infectious disease physicians in England have been diagnosing and managing occasional cases of viral hemorrhagic fever since 1971, including the United Kingdom's first case of Ebola virus disease in 1976. Specialist isolation facilities to provide safe and effective care have been present since that time. Following the emergence of Middle East respiratory syndrome (MERS) in 2012, and the avian influenza A (H7N9) outbreak in 2013, and the 2014-2016 Ebola virus disease outbreak in West Africa, clinical and public health preparedness and response pathways in England have been strengthened for these types of diseases, now called high-consequence infectious diseases (HCIDs). The HCID program, led by NHS England and Public Health England between 2016 and 2018, helped to deliver these enhancements, which have since been used on multiple occasions for new UK cases and outbreaks of MERS, mpox, avian influenza, and Lassa fever. Additionally, HCID pathways were activated for COVID-19 during the first 3 months of 2020, before the pandemic had been declared and little was known about COVID-19 but HCID status had been assigned temporarily to COVID-19 as a precaution. The HCID program also led to the commissioning of a network of new airborne HCID treatment centers in England, to supplement the existing network of contact HCID treatment centers, which includes the United Kingdom's only 2 high-level isolation units. In this case study, the authors describe the airborne and contact HCID treatment center networks in England, including their formation and structures, their approach to safe and effective clinical management of patients with HCIDs in the United Kingdom, and challenges they may face going forward.


Assuntos
COVID-19 , Humanos , Inglaterra/epidemiologia , COVID-19/epidemiologia , Hospitalização , Surtos de Doenças/prevenção & controle , Doenças Transmissíveis/epidemiologia , Doenças Transmissíveis/terapia , Controle de Doenças Transmissíveis/organização & administração , Controle de Doenças Transmissíveis/métodos , SARS-CoV-2 , Influenza Humana/epidemiologia
2.
BMJ Case Rep ; 13(6)2020 Jun 16.
Artigo em Inglês | MEDLINE | ID: mdl-32546557

RESUMO

A 33-year-old man presented repeatedly with severe abdominal pain and diarrhoea. Renal colic was suspected, and he was admitted for pain management. Questioning elicited an additional history of sore throat and mild, dry cough. Inflammatory markers were mildly raised (C reactive protein (CRP) 40 mg/L). Initial nasopharyngeal swabs were negative for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) by PCR. CT of the kidneys, ureters and bladder (CT KUB) was normal; however, CT of the thorax showed multifocal bilateral peripheral areas of consolidation consistent with COVID-19 infection. He developed respiratory compromise and was transferred to the intensive care unit (ICU). Sputum was positive for SARS-CoV-2 by PCR, and culture grew Yersinia enterocolitica He recovered following supportive management and treatment with piperacillin-tazobactam.


Assuntos
Dor Abdominal , Betacoronavirus/isolamento & purificação , Infecções por Coronavirus , Pulmão/diagnóstico por imagem , Pandemias , Combinação Piperacilina e Tazobactam/administração & dosagem , Pneumonia Viral , Dor Abdominal/diagnóstico , Dor Abdominal/etiologia , Adulto , Antibacterianos/administração & dosagem , COVID-19 , Infecções por Coronavirus/diagnóstico , Infecções por Coronavirus/fisiopatologia , Infecções por Coronavirus/terapia , Cuidados Críticos/métodos , Diagnóstico Diferencial , Diarreia/diagnóstico , Diarreia/etiologia , Humanos , Masculino , Pneumonia Viral/diagnóstico , Pneumonia Viral/etiologia , Pneumonia Viral/fisiopatologia , Pneumonia Viral/terapia , SARS-CoV-2 , Escarro/microbiologia , Tomografia Computadorizada por Raios X/métodos , Resultado do Tratamento , Yersinia enterocolitica/isolamento & purificação
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA